Ivermectin: panacea for resource-poor communities?

Ōmura, Satoshi; Crump, Andy

doi:10.1016/j.pt.2014.07.005

Cited by 147 publications

(102 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tetranactin, a cyclic antibiotic produced by Streptomyces aureus with a molecular structure related to cyclosporine, is used as emulsion against carmine mites of fruits and tea. A true success story in terms of anthelmintics is ivermectin (443), which is a dehydro derivative of avermectin produced by Streptomyces avermitilis. After its appearance in the late 1970s, ivermectin was the world's first endectocide, which at the time was a completely novel class of antiparasitic agents, with strong and broad-spectrum activity against both internal and external nematodes and arthropods.…”

Section: Actinobacteria As Sources Of Insecticidesmentioning

confidence: 99%

Taxonomy, Physiology, and Natural Products of Actinobacteria

Barka

Vatsa

Sanchez

et al. 2016

Microbiol Mol Biol Rev

1,592

1,048

View full text Add to dashboard Cite

SUMMARYActinobacteriaare Gram-positive bacteria with high G+C DNA content that constitute one of the largest bacterial phyla, and they are ubiquitously distributed in both aquatic and terrestrial ecosystems. ManyActinobacteriahave a mycelial lifestyle and undergo complex morphological differentiation. They also have an extensive secondary metabolism and produce about two-thirds of all naturally derived antibiotics in current clinical use, as well as many anticancer, anthelmintic, and antifungal compounds. Consequently, these bacteria are of major importance for biotechnology, medicine, and agriculture.Actinobacteriaplay diverse roles in their associations with various higher organisms, since their members have adopted different lifestyles, and the phylum includes pathogens (notably, species ofCorynebacterium,Mycobacterium,Nocardia,Propionibacterium, andTropheryma), soil inhabitants (e.g.,MicromonosporaandStreptomycesspecies), plant commensals (e.g.,Frankiaspp.), and gastrointestinal commensals (Bifidobacteriumspp.).Actinobacteriaalso play an important role as symbionts and as pathogens in plant-associated microbial communities. This review presents an update on the biology of this important bacterial phylum.

show abstract

Section: Actinobacteria As Sources Of Insecticidesmentioning

confidence: 99%

Taxonomy, Physiology, and Natural Products of Actinobacteria

Barka

Vatsa

Sanchez

et al. 2016

Microbiol Mol Biol Rev

1,592

1,048

View full text Add to dashboard Cite

show abstract

“…The insecticidal properties of IVM make it attractive as an alternative control tool for malaria [25] and other vector-borne diseases, including leishmaniasis and trypanosomiasis [27]. Its short half-life, however, could limit its widespread application.…”

Section: Discussionmentioning

confidence: 99%

“…Mass drug administration (MDA) with IVM has been advocated as a complementary vector control strategy [25,26]. Potential benefits include: i) a novel mechanism of action [27] compared to currently used insecticides, which could circumvent resistance; ii) effectiveness against malaria vectors regardless of place or time of the feeding; and, iii) additional effects inhibiting Plasmodium sporogony [28]. …”

Section: Introductionmentioning

confidence: 99%

Screening for an ivermectin slow-release formulation suitable for malaria vector control

Chaccour

Barrio

Royo

et al. 2015

Malar J

View full text Add to dashboard Cite

BackgroundThe prospect of eliminating malaria is challenged by emerging insecticide resistance and vectors with outdoor and/or crepuscular activity. Ivermectin can simultaneously tackle these issues by killing mosquitoes feeding on treated animals and humans. A single oral dose, however, confers only short-lived mosquitocidal plasma levels.MethodsThree different slow-release formulations of ivermectin were screened for their capacity to sustain mosquito-killing levels of ivermectin for months. Thirty rabbits received a dose of one, two or three silicone implants containing different proportions of ivermectin, deoxycholate and sucrose. Animals were checked for toxicity and ivermectin was quantified periodically in blood. Potential impact of corresponding long-lasting formulation was mathematically modelled.ResultsAll combinations of formulation and dose released ivermectin for more than 12 weeks; four combinations sustained plasma levels capable of killing 50% of Anopheles gambiae feeding on a treated subject for up to 24 weeks. No major adverse effects attributable to the drug were found. Modelling predicts a 98% reduction in infectious vector density by using an ivermectin formulation with a 12-week duration.ConclusionsThese results indicate that relatively stable mosquitocidal plasma levels of ivermectin can be safely sustained in rabbits for up to six months using a silicone-based subcutaneous formulation. Modifying the formulation of ivermectin promises to be a suitable strategy for malaria vector control.Electronic supplementary materialThe online version of this article (doi:10.1186/s12936-015-0618-2) contains supplementary material, which is available to authorized users.

show abstract

“…Oral ivermectin has been available commercially for years; it was first approved for the treatment of scabies in France in 2001, where it is licensed for the treatment of outbreaks in residential homes [66]. In recent years it has gained approval in Australia, New Zealand, Japan, Germany and the Netherlands [52, 67]. Ivermectin is not licensed for treating scabies or any other condition in the UK; it can be prescribed off-label but is expensive and available only on a named-patient basis for the treatment of crusted scabies, from “special order” manufacturers or specialist importing companies.…”

Section: Treatmentmentioning

confidence: 99%

A Review of Scabies: An Infestation More than Skin Deep

2018

View full text Add to dashboard Cite

Human scabies, a common infestation, has a worldwide distribution with a variable impact and presentation depending on the clinical situation. In developed, high-income settings, health institution and residential home outbreaks challenge health and social care services. In resource-poor settings, it is the downstream sequelae of staphylococcal and streptococcal bacteraemia, induced by scratching, which have a significant impact on the long-term health of communities. Over the past decade scabies has been recognised as a “neglected tropical disease” (NTD) by the World Health Organisation, has an accepted practical system of global diagnostic criteria and is being adopted into integrated programmes of mass drug administration for NTDs in field settings. This review seeks to summarise the recent advances in the understanding of scabies and highlight the advocacy and research headlines with their implication for diagnosis and management of outbreaks and individuals. In addition, it will indicate the priorities and questions that remain.

show abstract

Ivermectin: panacea for resource-poor communities?

Cited by 147 publications

References 69 publications

Taxonomy, Physiology, and Natural Products of Actinobacteria

Taxonomy, Physiology, and Natural Products of Actinobacteria

Screening for an ivermectin slow-release formulation suitable for malaria vector control

A Review of Scabies: An Infestation More than Skin Deep

Contact Info

Product

Resources

About